Nyxoah reports Preliminary Q4 results
Source: SeekingAlpha
2026-01-12 16:12:16 ET
More on Nyxoah
- Nyxoah SA (NYXH) Q3 2025 Earnings Call Transcript
- Nyxoah’s Genio therapy gets significant 2026 Medicare reimbursement increases under final CMS rule
- Nyxoah announces multi-part financing totaling up to €84M
- Seeking Alpha’s Quant Rating on Nyxoah
- Historical earnings data for Nyxoah
Read the full article on Seeking Alpha
For further details see:
Nyxoah reports Preliminary Q4 results
Nyxoah SA
NASDAQ: NYXH
NYXH Trading
2.65% G/L:
$3.49 Last:
18,961 Volume:
$3.55 Open:
NYXH Latest News
March 11, 2026 05:05:00 pm
Nyxoah to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
March 05, 2026 04:05:00 pm
Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
February 18, 2026 04:05:00 pm
Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East
January 21, 2026 04:05:00 pm
Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth
NYXH Stock Data
$174,972,464
20,023,587
N/A
13
N/A
Medical Equipment & Supplies
Healthcare
BE
Mont-Saint-Guibert
